The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.


INTRODUCTION Biologic markers that predict development of invasive breast cancer (IBC) in patients diagnosed with ductal carcinoma in situ (DCIS) are needed to improve personalized therapy. In this study, we examined the incidence of early IBC in DCIS subgroups defined by immunophenotype. METHODS Clinical and histologic materials of 143 patients with… (More)
DOI: 10.1002/jso.21973

6 Figures and Tables


  • Presentations referencing similar topics